In a letter to doctors, the company and the Food and Drug Administration, warned about the risk of serious infection and decreased blood platelets that could be associated with consumption of the medication.
Raptiva won U.S. approval in October 2003 to treat adults with chronic plaque psoriasis, a skin condition known for giving red, scaly patches.
Two cases of hemolytic anemia, caused by premature destruction of red blood cells, have been reported since Raptiva hit the market; as well as serious infections, including bacterial sepsis. and severe pneumonia.
